



# NATIONAL HEMOPHILIA FOUNDATION

*for all bleeding disorders*

## Board of Directors

### Officers

**Gina Shreve, PhD, President**  
Wayne State University  
Ann Arbor, Michigan

**Jordan Lurie, MD, President-Elect**  
Metro Denver Anesthesia  
Castle Rock, Colorado

**Calvin Price, Treasurer**  
University of Utah Hospital  
Midvale, Utah

**Nikki J. Beneke, PT, Secretary**  
Dallas, Texas

### Directors

**Stephen Bender**  
Bana Electric Corp  
Farmingdale, New York

**Ross Bruner**  
Tri Star Management  
New York, New York

**Edward Burke**  
Caremark Health Services  
Palrn Harbor, Florida

**Paula M. Elbirt, MD**  
New York, New York

**Steven Faust**  
Atlanta, Georgia

**Elizabeth Fung, MSW, PhD**  
Children's Memorial Hospital  
Chicago, Illinois

**Carletha G. Gates, MPA**  
Curative Health Services  
Bowie, Maryland

**Jonathan C. Goldsmith, MD**  
Baltimore, Maryland

**Rita R. Gonzales**  
The Switchboard  
Houston, Texas

**Paul F. Haas**  
Bowling Green State University  
Bowling Green, Ohio

**Mark Homonoff, MD**  
New York, New York

**Jerry Hooper**  
Franklin, Tennessee

**Keith Hoots, MD**  
Gulf States Hemophilia &  
Thrombophilia Center  
Houston, Texas

**Andra H. James, MD, MPH**  
Duke University  
Durham, North Carolina

**Gregory Karfoot**  
Naperville, Illinois

**Bruce P. King**  
Dartmouth-Hitchcock Medical Center  
Lebanon, New Hampshire

**Richard Metz, MD**  
Los Angeles, California

**Glenn Pierce, PhD, MD**  
Avigen  
Rancho Santa Fe, California

**Carlos Ruiz**  
Miami VA Medical Center  
Miami Lakes, Florida

**Jan van Eys, PhD, MD**  
Vanderbilt University School of Medicine  
Nashville, Tennessee

**Shirley Wilson**  
Ramsey, Minnesota

**Richard T. Hellner**  
Chief Executive Officer

3051 '03 JUN 19 A10:15  
June 12, 2003

Dockets Management Branch (HFA-305)  
U.S. Food and Drug Administration  
5630 Fishers Lane, Room 1061  
Rockville, Maryland 20852

Re: Bar Code Label for Human Drug Products and Blood; Proposed Rule

Dear Sirs:

Thank you for the opportunity to comment on the proposed bar code label requirements for human drugs and biologicals published in the March 14, 2003 *Federal Register*. The National Hemophilia Foundation (NHF) is the national voluntary health organization dedicated to improving the health and welfare of people with hemophilia, von Willebrand disease, and other bleeding disorders.

In reviewing the notice, NHF and the hemophilia medical and scientific community strongly encourage the Food and Drug Administration (FDA) to strengthen the proposal by requiring the inclusion of additional product information on the bar code. We understand FDA proposes to include only the National Drug Code in the bar code, but feel the bar code label for clotting factor products should include all of the following information:

1. The product brand name,
2. Lot number,
3. Expiration date, and
4. Number of units contained in the vial.

NHF recognizes the potential difficulties of this latter point, as the units per vial for these products vary between lots within an approved range. Labeling must occur on both the package box and the vial, as persons with hemophilia and other bleeding disorders often carry vials, but not always the box, with them.

Overall, the additional product information on the bar code will improve product tracking when needed for adverse events, recalls and withdrawals and will provide better information about the efficacy of the product, i.e., did the patient achieve the expected hemostatic response given the units administered.

02N-0204

C112


116 West 32nd Street • 11th Floor  
New York, NY 10001

(800) 42-HANDI • (212) 328-3700 • fax (212) 328-3777  
www.hemophilia.org • info@hemophilia.org

NHF also encourages the development of similar bar coding requirements for implantable medical devices, such as ports, central lines, and artificial joints, as this information currently is inconsistently recorded.

Thank you again for the opportunity to comment on the proposed bar coding rule. We applaud FDA's efforts to reduce medical errors and support the inclusion of additional information on the bar code to further support this goal.

Sincerely,

A handwritten signature in black ink that reads "Gina A. Shreve". The signature is written in a cursive style with a large initial "G" and "S".

Gina Shreve, Ph.D.  
President